Source: International Congress 2019 – Interstitial lung disease registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kreuter (Heidelberg, Germany), H. Kabitz (Konstanz, Germany), L. Hagmeyer (Solingen, Germany), P. Hammerl (Immenhausen, Germany), A. Esselmann (Warendorf, Germany), C. Wiederhold (Fulda, Germany), D. Skowasch (Bonn, Germany), C. Stolpe (Ibbenbüren, Germany), M. Joest (Bonn, Germany), S. Veitshans (Böblingen, Germany), P. Maqhuzu (Neuherberg, Germany), L. Schwarzkopf (Munich, Germany), A. Hellmann (Augsburg, Germany), M. Pfeifer (Donaustauf, Germany), J. Behr (Munich, Germany), D. Kauschka (Essen, Germany), A. Günther (Giessen, Germany), F. Herth (Heidelberg, Germany), P. Markart (Fulda, Germany). Treatment and survival diversities in different forms of ILD in Germany - EXCITING registry. 4725

Member's Comments

No comment yet.

Related content which might interest you: ILD registries in Germany: INSIGHTS-IPF Source: International Congress 2016 – Interstitial lung disease registry Year: 2016 Phenotypes, treatable traits, GOLD groups and grades – how they predict mortality risk in COPD patients? (data from the Czech Multicenter Research Database of COPD) Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Disease management program COPD in Germany: benefit for the patient in respect of GOLD-stages? Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 Real life distribution of the COPD patients in GOLD groups A to D in German population: DACCORD registry Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE) Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Late Breaking Abstract - Analysing the COPD care pathway in Japan, Canada, England and Germany: pilot study results Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Epidemiology and mortality of non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung disease (PF-ILD) using the French national health insurance system (SNDS) database in France: the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Use of prognostic indicators to identify patients with end stage COPD: A survey of South-West (SW) England clinicians Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 Incidence and clinical characteristics of lung cancer in patients with COPD - From Hokkaido COPD cohort study Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Functional decline over time in patients with IPF treated with pirfenidone: the PROOF registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Assessment of quality of life (SGRQ) in patients with alpha-1-antitrypsin deficiency– Analysis from the German registry Source: International Congress 2016 – Non-inflammatory COPD monitoring Year: 2016 ILD India registry: results from the new ILD India Registry database Source: International Congress 2016 – Interstitial lung disease registry Year: 2016 2-Year survival of patients with IPF with or without GERD: a study using VA national database Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Ten-year projected outcomes associated with increased use of triple therapies in UK patients with COPD using the COPD Health Outcome Policy and INtervention (CHOPIN) model Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Utilization of FIXED combination (FC) in the treatment of asthma patients in real life condition in the Czech Republic (UFO) Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 The incidence of severe alpha-1-antitrypsin (AAT) deficiency alleles in COPD patients – Preliminary results from Central Eastern European (CEE) AAT NETWORK Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 The economic burden of COPD in a Swedish cohort: The ARCTIC study Source: International Congress 2016 – Screening, diagnosis, assessment, and treatment of COPD in primary care Year: 2016 COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Clinical outcomes and use of 4C mortality scoring in COVID-19 patients treated with Remdesivir in a large UK centre Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021